Current Report Filing (8-k)
March 18 2019 - 9:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 18, 2019
Vaccinex, Inc.
(Exact
name of Registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-38624
|
|
16-1603202
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
1895 Mount Hope Avenue, Rochester, New York
|
|
14620
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (585)
271-2700
N/A
(Former name or former address, if changed since last report
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the Registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or
Rule 12b-2 of
the Securities Exchange Act of
1934 (§240.12b-2 of
this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
|
Item 7.01
|
Regulation FD Disclosure.
|
On March 18, 2019, Vaccinex, Inc. (the “Company”) updated the corporate presentation available on its website located at
www.vaccinex.com
under the heading “Investors” and subheading “Events & Presentations.” A copy of the Company’s updated corporate presentation is attached to this Current Report on Form
8-K
(the “Report”) as Exhibit 99.1.
The information furnished pursuant to this Item 7.01,
including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities under such section and shall not
be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
Neither the filing of any exhibit to this Report nor the inclusion in such exhibit or this Report of a reference to the
Company’s Internet address shall, under any circumstances, be deemed to incorporate the information available at such address into this Report. The information available at the Company’s Internet address is not part of this Report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Vaccinex, Inc.
|
|
|
|
|
|
Date: March 18, 2019
|
|
By:
|
|
/s/ Scott E. Royer
|
|
|
|
|
|
Scott E. Royer
|
|
|
|
|
|
Chief Financial Officer
|
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaccinex (NASDAQ:VCNX)
Historical Stock Chart
From Apr 2023 to Apr 2024
